Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00266786
Registration number
NCT00266786
Ethics application status
Date submitted
16/12/2005
Date registered
19/12/2005
Date last updated
8/02/2017
Titles & IDs
Public title
Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery
Query!
Scientific title
A Phase 3, Double-Blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain Following Major Abdominal Surgery
Query!
Secondary ID [1]
0
0
ROX 2005-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Postoperative Pain
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Intranasal Ketorolac Tromethamine
Treatment: Drugs - Intranasal Placebo
Experimental: Intranasal Ketorolac Tromethamine -
Placebo Comparator: Intranasal Placebo -
Treatment: Drugs: Intranasal Ketorolac Tromethamine
Intranasal at 30mg
Treatment: Drugs: Intranasal Placebo
Intranasal Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Summed Pain Intensity Difference (SPID) on Day 1
Query!
Assessment method [1]
0
0
Ratings of Pain Intensity (PI) were made using a 100-mm Visual Analog Scale (VAS) on which 0 = no pain and 100 = worst pain possible. The PI values were obtained every hour following the first dose of study medication on Day 1. Pain intensity difference (PID) was calculated by subtracting the posttreatment score from the baseline score, where the baseline score was the PI rating made prior to the first dose of study medication. A summed PID (SPID) on the first postoperative day was calculated at 6 hours.
Query!
Timepoint [1]
0
0
6 hours after drug administration
Query!
Secondary outcome [1]
0
0
Pain intensity difference scores
Query!
Assessment method [1]
0
0
Ratings of Pain Intensity (PI) were made using a 100-mm Visual Analog Scale (VAS) on which 0 = no pain and 100 = worst pain possible. PID was calculated by subtracting the posttreatment score from the baseline score, where the baseline score was the PI rating made prior to the first dose of study medication.
Query!
Timepoint [1]
0
0
Prior to receiving study drug and at 20, 40, and 60 minutes, and 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours after the first dose, then prior to each dose up to 72 hours
Query!
Secondary outcome [2]
0
0
Quality of analgesia
Query!
Assessment method [2]
0
0
Quality of analgesia was assessed on a 5-point categorical scale with 0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent.
Query!
Timepoint [2]
0
0
Prior to receiving study drug and at 20, 40, and 60 minutes, and 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours after the first dose, then prior to each dose up to 72 hours
Query!
Secondary outcome [3]
0
0
Global assessment of pain control
Query!
Assessment method [3]
0
0
A global evaluation of pain control was conducted once daily at bedtime using a 5-point categorical scale on which 0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent.
Query!
Timepoint [3]
0
0
8 hours following first dose of study medication
Query!
Secondary outcome [4]
0
0
Morphine sulfate consumption at 24, 48, and 72 hours
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
24, 48, and 72 hours after drug administration
Query!
Eligibility
Key inclusion criteria
- Men or women age 18 through 64 years
- Major abdominal surgery
- Body weight = 100 and = 300 pounds
- Negative serum pregnancy test
- Pain intensity score at least 40 (moderate pain) on 100 mm visual analog scale
- Minimum 48 hour hospital stay and 5 day maximum stay
- Able to provide written informed consent
- Willing and able to comply with all testing requirements of the protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
64
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Allergy or sensitivity to ketorolac or ethylene diamine tetraacetic acid (EDTA)
- Allergy or significant reaction to opioids
- Allergic reaction to aspirin or other nonsteroidal anti-inflammatory drug (NSAIDs)
- Current upper respiratory tract infection or other respiratory tract condition that
could interfere with absorption of the nasal spray or adverse event assessment
- Use of any intranasal product in past 24 hours
- Clinically significant abnormality on screening lab tests
- History of cocaine use
- Active peptic ulcer disease or significant history of peptic ulcer disease or
gastrointestinal bleeding
- Advanced renal impairment or risk for renal failure
- History of other medical problems that could interfere with the study participation
- Pregnancy or breastfeeding
- Participation in another investigational study within past 30 days
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
321
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Texas
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Hamilton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Egalet Ltd
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Ketorolac has been marketed for several years in other forms (tablet and injectable) for the
short-term relief of pain. This study will test whether a new dosage form (nasal spray)
containing ketorolac is effective at relieving the pain of major abdominal surgery, and will
also assess product safety. Previous studies with the nasal spray have suggested that it is
similar to the previously approved injectable form in effectiveness for pain relief and in
its safety profile.
Patients will be randomized in a 2:1 ratio to receive intranasal ketorolac or placebo when
the pain reaches a moderate level (40 on a scale of 100) following surgery. After the first
dose, subjects will receive study drug every 6 hours for 48 hours, and then as needed (up to
4 times a day) for a total of 5 days. If pain is not adequately relieved by the study drug,
subjects will be given morphine sulfate or other standard analgesics. Follow-up safety
evaluations will occur about 1 and 2 weeks after the start of dosing.
Subjects will be asked to answer questions about their pain relief and any possible side
effects of the drug during the study, and will be given physical examinations, including
nasal evaluations, before and during the clinical trial. A small amount of blood will be
drawn for routine clinical laboratory testing.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00266786
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Lincoln Bynum, MD
Query!
Address
0
0
ICON Clinical Research
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00266786
Download to PDF